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Abstract 
During the past two decades, extracellular vesicles (EVs) have been identified as important 
mediators of intercellular communication, enabling the functional transfer of bioactive molecules 
from one cell to another. Consequently, it is becoming increasingly clear that these vesicles are 
involved in many (patho)physiological processes, providing opportunities for therapeutic 
applications. Moreover, it is known that the molecular composition of EVs reflects the 
physiological status of the producing cell and tissue, rationalizing their exploitation as biomarkers 
in various diseases. In this review the composition, biogenesis and diversity of EVs is discussed in 
a therapeutic and diagnostic context. We describe emerging therapeutic applications, including the 
use of EVs as drug delivery vehicles and as cell-free vaccines, and reflect on future challenges for 
clinical translation. Finally, we discuss the use of EVs as a biomarker source and highlight recent 
studies and clinical successes. 
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1. Introduction 
1.1. A brief historical overview of EVs 
In addition to single molecules (i.e. small molecules, peptides and proteins), macromolecular 
complexes (e.g. Argonaute2 (AGO2)-RNA complex) and lipoproteins, cells also release 
membrane-enclosed vesicles in the extracellular medium. The first reports on such extracellular 
vesicles (EVs) date back to the late 1960s when it was observed that platelet free plasma contains 
vesicular material that could be pelleted down by ultracentrifugation (UC). These vesicles were 
mainly composed of phospholipids and appeared to promote blood clothing [1] and cartilage 
calcification [2]. In the decades that followed, using electron microscopy imaging, vesicular 
structures could be visualized in calf serum [3] and the first observations were made on tumor cell-
derived membrane vesicles [4]. Initially it was assumed that the observed vesicles were solely 
released by outward budding of the cell membrane. Several years later, Johnstone and colleagues 
reported on the formation of intraluminal vesicles (ILVs) in late endosomes by inward budding of 
the endosomal limiting membrane. Following fusion of these so-called multivesicular bodies 
(MVBs) with the cell’s plasma membrane, the ILVs are released in the surrounding fluid [5, 6]. 
This discovery was made based on the observation that reticulocytes release their transferrin 
receptor, as part of the maturation into erythrocytes, associated to vesicles. As this mechanism was 
also observed in other species and appeared to be selective for certain membrane-associated 
proteins [7], these EV were initially presented as a conserved and regulated waste removal pathway 
[8]. A seminal paper by Raposo et al. in 1996, reporting on the immune-modulating activity of B 
cell-derived EVs, inspired many others to evaluate the biological implications of these vesicles [9]. 
Two years later, Zitvogel et al. used EVs derived from tumor peptide-pulsed dendritic cells (DCs) 
as a cell-free anti-cancer vaccine providing the first therapeutic application of EVs [10]. Among 
others, these reports introduced the notion that EVs cannot solely be considered as a waste disposal 
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mechanism but also as important mediators of intercellular communication. Owing to the work of 
many, it was becoming increasingly clear that EVs likely play a fundamental role in many 
(patho)physiological processes. Besides deciphering the biological function of EVs, their potential 
as biomarker source [11, 12] was recognized and the first clinical trials using EVs as an anti-cancer 
vaccine were initiated [13]. In addition, around a decade ago different groups identified the 
presence of miRNA, mRNA and proteins in EVs and, more importantly, the ability to functionally 
shuttle their cargo into recipient cells, reinforcing the belief that EVs facilitate communication 
between cells [14, 15] and fuelling the idea of exploiting these vesicles for drug delivery 
applications. 
1.2. Biogenesis, cargo loading and composition  
Generally, EVs are categorized in three subtypes (i.e. exosomes, ectosomes and apoptotic bodies), 
based on distinct biogenesis pathways [16]. Apoptotic bodies are formed when a cell is dying via 
apoptosis, leading to blebbing and finally disintegration of the cell plasma membrane with 
partitioning of the cellular content in different membrane-enclosed vesicles. Hence, apoptotic 
bodies typically are larger particles (~0.5 - 4 µm) containing cytoplasmic organelles and 
fragmented nuclei [17]. Although some studies have reported a communication and biological 
function for these vesicles [18, 19], most research in this field discusses the smaller sized exosomes 
and ectosomes. Hence, apoptotic bodies are not considered when referring to EVs throughout this 
review. Exosomes (50 – 150 nm) and ectosomes (50 – 1000 nm) do not only show a partly 
overlapping size distribution but also their biogenesis pathways are very similar (figure 1A). In 
both cases their formation is preceded by the assembly of membrane micro-domains composed of 
specific lipids (with an important role for ceramide) [20] and proteins followed by budding and 
subsequent fission or pinching off. The main difference between both formation pathways is the 
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location of the initial budding process. Indeed, ectosomes (also termed shedding vesicles or 
microvesicles) are released directly from the cell’s plasma membrane. On the other hand, exosomes 
originate from the inward budding of early and late endosomes hence forming MVBs containing 
ILVs [21, 22]. Subsequently, the MVBs are transported to and fuse with the plasma membrane, 
requiring a dynamic interplay between members of the Rab and SNARE protein family, 
concurrently releasing the ILVs in the extracellular space [23-27]. Partly because both biogenesis 
pathway are analogous, to date there is no defined panel of markers to distinguish between both 
vesicle subtypes in a vesicular isolate. Nonetheless, a panel of generic markers (e.g. CD9, CD81, 
CD63, TSG101, etc.) was defined by the International Society of Extracellular Vesicles (ISEV) to 
indicate the presence of EVs in a sample [28].  
Figure 1. Schematic representation of EV biogenesis and architecture. [A] The 
biogenesis pathways of exosomes and ectosomes or shedding vesicles. Exosomes 
are formed by inward budding of the limiting membrane of early or late endosomes 
(LE) forming multivesicular bodies (MVBs) containing so-called intra-luminal 
vesicles (ILVs). Upon fusion of the MVBs with the cell membrane, the ILVs are 
released as exosomes in the extracellular medium. In contrast, ectosomes are 
released by direct budding from the plasma membrane. [B] The molecular 
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architecture of extracellular vesicles with some key general and cell-type specific 
molecular components. General: Tetraspanins (e.g. CD63, CD81), Alix, Heat shock 
proteins (e.g. Hsp70), major histocompatibility complex (MHC)-I, structural 
proteins (e.g. actin) , nucleic acids (e.g. miRNA, mRNA), integrins (type of integrin 
can be cell-type specific), lysobisphosphatidic acid (LBPA), cholesterol, 
ganglioside GM3 [29, 30]. Cell type specific: MHC-II, CD80, CD86 and 
complement shielding proteins CD55/59 (in DC) [31], tumor-associated antigens 
(TAA; e.g. GP100 in melanoma cells) [32], perforin (in natural killer T cells) [33]. 
 
Numerous papers report that the relative molecular composition of EVs differs distinctly from the 
producer cell. Lipidomic analysis showed an accumulation of cholesterol, sphingomyelin, 
glycerophospholipids and phosphatidylserine (PS) in EVs [34]. Certain membrane-associated 
proteins, for example many tetraspanins (e.g. CD9, CD81), appear enriched on the EV surface [35]. 
Finally, an array of reports show that specific mRNAs, miRNAs and other non-coding RNAs (e.g. 
t-RNA, Y-RNA, vault RNA, etc.) are enriched or underrepresented in EVs compared to their 
respective parent cells [36-41]. Based on these observations it is generally accepted that the 
composition of EVs is, at least partially, actively regulated by the parent cell [42], albeit that the 
mechanisms and associated key players regulating this cargo sorting remain largely elusive to date 
[38, 43-46].  
The overall EV configuration (i.e. a lipoprotein shell encapsulating an aqueous core containing 
soluble proteins and nucleic acids) and part of the molecular composition (i.e. proteins and lipids 
required in the EV biogenesis) are common among EVs isolated from different cells [29]. However, 
some EV-associated molecules are unique for the producing cell type (figure 1B). For example, 
MHC II is found on EVs secreted by antigen presenting cells (APC) [35, 47]. As another example, 
CD2, CD8 and CD56 were found in EVs derived from natural killer (NK) cells and not in EVs 
derived from platelets where the opposite holds true for CD41b, CD42a and CD61 [48].  
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Furthermore, it appears that the culture conditions not only influence the cellular phenotype but 
also the number and/or composition of the secreted EVs. For instance, hypoxia triggers cancer cells 
to release more CD63-positive vesicles [49] with a modified molecular composition and distinct 
effect on recipient cells [50]. Comparable observations were made for an altered extracellular pH 
[51] and the presence of stress-inducing molecules (e.g. lipopolysaccharide, H2O2, etc.) in general 
[52]. Besides the cellular microenvironment also the status of the cell influences the EV 
composition and downstream activity. Where mature DCs release pro-inflammatory EVs enriched 
in MHC II and ICAM-1 [53], EVs derived from DCs cultured in the presence of IL10, an anti-
inflammatory cytokine, suppress the onset of inflammation in a mouse arthritis model [54]. The 
fact that phenotypic alterations in the parent cells are mirrored by the composition of the secreted 
EVs can be exploited for diagnostic purposes (section 3.2.). 
The influence of the surrounding medium on the EV composition may have relevant clinical 
implications. For instance, Li et al. compared EVs derived from N2A neuroblastoma cells cultured 
both in serum containing cell medium or under starvation conditions, showing marked alterations 
in the protein composition [55]. Besides the changes in the composition of the EV itself, the 
presence or absence of serum proteins will likely also influence the protein corona surrounding the 
EVs . It is well documented that this corona strongly influences the extra- and intracellular 
(transfection) behavior of synthetic nanoparticles, including liposomes [56, 57]. Given the analogy 
between EVs and liposomes [58] it is conceivable that a protein corona will also impact the EV 
interactome and hence biological function. However, to date the influence of these parameters on 
the EV functionality has not been thoroughly investigated. 
1.3. EV heterogeneity 
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Evidence is mounting that within the exosome and ectosome population many distinct vesicle 
subtypes exist. When a specific exosome release pathway (i.e. via Rab27a inhibition) was silenced, 
the secretion of only a specific set of exosome-related molecules (i.e. CD63, Tsg101, Alix and 
Hsc70) decreased whereas others (CD9 and Mfge8) were not affected [59]. This could indicate that 
different exosome subtypes exist originating from different biogenesis pathways. Additionally, 
Van Niel et al. showed a clear discrepancy in protein profile between EVs released from the apical 
or basolateral side of polarized epithelial cells [60]. Another report showed that vesicles isolated 
from conditioned cell medium and plasma by UC could be divided in two distinct populations by 
bottom-up density gradient UC. Both populations showed a different protein and nucleic acid 
composition, which correlated with a distinct biological effect on recipient cells [61]. To address 
this heterogeneity in more detail, more sensitive techniques have to be developed allowing single 
vesicle analysis. In this respect, a recent study by Smith and coworkers used Raman 
microspectroscopy to obtain a Raman spectrum, which can be regarded as a molecular fingerprint, 
on the single vesicle level. Following principal component analysis of the obtained spectra, these 
authors concluded that at least four types of vesicles with a clearly distinct molecular composition 
are released [62]. Conceivably, this is still an underestimation of the factual heterogeneity among 
EVs. Yet to date it is impossible to physically separate these specific EV subtypes as reliable 
markers are lacking. This implies that the composition of and functions attributed to EVs are likely 
the combined effect of multiple subtypes of vesicles. This notion further complicates the adoption 
of EVs in a pharmaceutical context as it is well possible that only a specific subfraction of vesicles 
induces a desired effect while others might entail off-target or even opposing effects. 
1.4. EV purification protocols and stability 
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EVs represent only a fraction of the cell’s secretome. Parallel to the growing research interest in 
EVs, different methods to isolate and purify EVs from conditioned cell medium or biological fluids 
have been developed. The most common approaches are listed in table 1 and discussed further 
with a focus on their applicability in a pharmaceutical context. The predominant technique in the 
literature is based on differential centrifugation followed by UC, which is based on a difference in 
size and density between EVs and other components present in the respective medium [63]. It is 
important to note that many potential contaminants are co-purified using UC (e.g. lipoprotein 
particles, protein(-RNA) aggregates, etc.) [64, 65]  and that the yield is relatively low (i.e. 10 – 
20%) and dependent on the medium viscosity [66, 67]. Additionally, the impact of the high shear 
forces on the vesicle integrity are under debate. While some studies indicate no changes in the 
integrity of the EVs after UC [68, 69] others show subtle EV aggregation influencing the EV 
biodistribution [70, 71]. 
To increase both the vesicle yield as well as purity of the isolate,  density gradient UC (iodixanol 
or sucrose) can be used [64, 72]. To underscore the superior separation resolution, it was shown 
that viral particles could be physically separated from EVs by using an iodixanol-based density 
gradient [73]. The major disadvantages of this technique are the long processing time, making this 
technology difficult to implement in a clinical setting [74], as well as the lack of knowledge 
regarding the effect of the density gradient media on the EV’s functionality and the potential 
interference of gradient residuals with downstream processing [28].  
Another method that was originally developed to concentrate viral particles [75], employs 
hydrophilic polymers (e.g. poly(ethylene glycol); PEG) and (high) salt concentrations to precipitate 
EVs. Although this method provides a high yield, which makes it interesting for small amounts of 
starting material or as a preparative concentrating step, it lacks specificity as many contaminants 
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(e.g. protein aggregates) are co-isolated [64]. Hence, interpreting downstream analysis of 
precipitated EV isolates, should be done with caution. Additionally, the PEG polymer is also 
present in the final isolate potentially shielding the EV surface and interfering with their 
functionality or downstream analysis [76].  
Affinity-based capture of EVs has the potential to yield subpopulations with high purity. The most 
well-known affinity-based approach exploits protein recognition on the EV surface via antibodies 
(e.g. associated to beads, a polymer surface in a chip or a chromatography column) [77, 78].  Of 
note, this method requires knowledge of specific EV markers, which despite many years of research 
[79] are still difficult to identify. To circumvent the lack of specific markers, a more general 
approach was recently presented in which antibodies are substituted by heparin as it appears to 
have a general affinity for EVs. However, the cross-reactivity with other components present in 
the respective media is a possible concern [80]. Overall, affinity-based capture of EVs might be 
very useful in an on-chip diagnostic set-up using small sample sizes [81, 82]. Yet from a therapeutic 
point of view, when contemplating to use EVs as medicinal products, larger volumes will have to 
be processed, thus augmenting manufacturing costs. Additionally, non-destructive methods to elute 
the EVs from the capturing agents need to be co-developed. 
Finally, several separation methods are being developed for EVs that exploit differences in size, 
including size-exclusion chromatography (SEC) and filtration [83]. SEC enables fast sample 
processing with high yield making it applicable in a clinical setting [70, 84]. However, sample 
dilution is inherent to the technique as well as co-purification of (a low percentage of) lipoproteins, 
which might limit the applicability of this technique in a diagnostic context [74, 83]. The main 
advantage of SEC is the mild conditions and hence retained EV functionality [85, 86]. On the other 
hand, sequential filtration steps can eliminate smaller and larger contaminants to concentrate EVs. 
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Yet a major disadvantage compared to SEC are the often high forces used (via air pressure or 
centrifugal forces) possibly compromising EV integrity. Moreover, sticking of EVs to the 
membrane filters might limit the yield [84]. In most cases filtration is used as a preparative step 
prior to one of the above mentioned techniques.  
Combining different purification methods based on complementary principles will be imperative 
to process very complex samples (e.g. plasma). The sequential combination of techniques is already 
commercially available, e.g. with the exo-spinTM system (CELL guidance systems). This approach 
merges an initial concentrating step using the precipitation method with subsequent SEC to 
enhance the sample purity. It is of note that the diversity of purification techniques used throughout 
the literature hampers unambiguous comparison of different studies. This is most pronounced in 
the field of biomarker discovery as it is clearly shown that different isolation methods might greatly 
alter the obtained RNA/protein profiles [64]. However, recently the amount of commercially 
available purification kits (e.g. ExoEasy Maxi kit, Qiagen; ExoPureTM Immunobeads, Biovision; 
qEV, Izon Science), based on different technologies, is increasing which is beneficial for the 
reproducibility and ability to compare between studies using the same kits. Retained vesicle 
integrity and functionality is of pivotal importance in a therapeutic context. In this regard, a direct 
comparison between different purification strategies evaluating the therapeutic functionality of the 
obtained vesicle isolates would provide valuable information for pharmaceutical applications.  
2. Therapeutic applications of EVs 
2.1. Harnessing the intrinsic biological effect of EVs 
As discussed above, EVs are composed of numerous potentially bioactive molecules (i.e. lipids, 
proteins, nucleic acids and carbohydrates) of which the relative composition is regulated by the 
producer cell. In this respect, it is no surprise that EVs have an intrinsic biological effect that 
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modulates the recipient cell’s phenotype, which can be exploited in a therapeutic context [87]. 
These phenotypical alterations can be elicited by a receptor-ligand interaction at the cellular surface 
[88, 89] or at the luminal side of the (late) endosomes, thus triggering a downstream signaling 
pathway [90]. Alternatively, it is believed that EVs can fuse with cellular membranes (plasma 
membrane and/or endosomal membrane) and release their content in the cytoplasm [91] (figure 2). 
 
Figure 2. Mechanisms behind EV-mediated phenotypical changes in recipient 
cells. (a) The EV surface proteins/lipids can interact with receptors on the recipient 
cell’s surface triggering an intracellular signaling pathway. Alternatively, (b) the 
EV cargo (e.g. proteins and nucleic acids) can be released in the cell’s cytoplasm 
via membrane fusion with the limiting cell membrane or (c) with the endosomal 
membrane after initial internalization via phagocytosis/endocytosis. Finally, it is 
also possible that the (d) EVs release their content (after partial degradation) in the 
endolysosomes where it can trigger endosomal receptors (e.g. toll-like receptors). 
As mentioned earlier, Raposo et al. showed that EVs derived from activated APCs could stimulate 
the immune system by presenting functional antigen-MHC complexes to T cells [9]. This 
observation was followed by many pre-clinical and clinical studies using antigen pulsed, DC-
derived EVs as a cell-free alternative for cancer vaccination (section 2.3.) [92]. 
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Another example of the use of EVs as a cell surrogate therapy are mesenchymal stem cell (MSC)-
derived vesicles. MSCs are stromal cells with multipotent differentiation capacity and have been 
intensively investigated for their potential regenerative and immunosuppressive effects in many 
animal models and clinical trials. Although originally believed to be the result of MSC homing to 
and engraftment at injured tissues, it is now becoming increasingly clear that the biological effect 
of these cells is mainly attributed to their secretome, including EVs [93, 94]. In this respect, MSC-
derived EVs have been studied in dedicated mouse models for their tissue-protective effects 
following acute kidney failure [93], myocardial infarct [95], liver injury [96] and neural injury after 
middle cerebrate artery occlusion [97]. Considering their immunosuppressive nature, MSC EVs 
are under investigation for a multitude of inflammatory conditions. For instance, in the field of 
auto-immune diseases, EVs shed by MSCs have shown to limit the pro-inflammatory response and 
induce a shift towards a beneficial regulatory T cell profile in type I diabetes [98] which is currently 
being investigated in a clinical setting (NCT02138331). As another example, MSC EVs are also 
successfully investigated in refractory graft-versus-host disease [99]. The exact mechanism behind 
the therapeutic effect of MSC-derived EVs remains largely obscure and is a topic of intensive 
investigation [100]. It is however known that stem cell EVs are enriched in signaling proteins, 
including cytokines, chemokines, interleukins and growth factors [101]. The use of EVs as a 
surrogate for cell-based therapies is intensively studied as it might entail some benefits. EVs are 
more resistant to freeze-thaw processes, are genetically stable making them a safer alternative to 
whole cells and they are likely less immunogenic allowing allogeneic therapy. Multiple 
comprehensive reviews have been published giving a more detailed overview of reported data on 
this topic [102, 103].  
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Next to their exploitation as surrogates for cell therapy, EVs from specific cell types have shown 
interesting features that can be exploited in a therapeutic context. For example, NK-cell derived 
EVs were shown to contain killer proteins (e.g. perforins), which are taken up by tumor cells and 
induce tumor cell death [33]. Adipose-derived stem cells (ADSCs) release EVs containing 
neprilysin (i.e. an A-degrading enzyme), which lowered the A-level secreted by N2A cells and 
thus might be a valuable therapy to investigate further in Alzheimer’s disease [104].  
It is of note that these reports have to be interpreted with careful consideration of the EV 
purification protocol used. Dependent on the selected method, non-EV contaminants can be co-
isolated, possibly leading to observations being incorrectly attributed to EVs. Moreover, many 
reports focus on a specific component of EVs, e.g. small non-coding RNA such as miRNAs, often 
neglecting the true complexity of the EV composition in which lipids and proteins likely also play 
a key role [105]. As a result of this complexity, EVs can simultaneously interfere with different 
signaling pathways, leading to pleiotropic effects. For example, it was observed that EVs derived 
from immortalized cardiomyocytes (HL-1 cells) significantly altered the expression of 161 genes 
in fibroblasts (NIH/3T3 cells) after co-culture [106]. This complexity implies that the observed 
effects are likely very difficult to mimic by synthetic, single-API drug therapies. On the other hand, 
care should be taken that this intrinsic complexity does not impede the translatability of EVs into 
a viable pharmaceutical product [107]. 
2.2. Harnessing EVs as a drug delivery vehicle 
2.2.1. Beneficial features of EVs as nanocarriers 
As outlined above, EVs are involved in communication between cells owing to their ability to 
deliver biomolecules from one cell type to another, thereby crossing both extra- and intracellular 
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barriers. Based on this particular feature, EVs are also envisioned as biological nanocarriers for the 
delivery of exogenous therapeutic (macro)molecules. The encapsulation of drugs in nanoparticles 
(creating so-called nanomedicines) is a well-established approach to (1) modify the 
pharmacokinetics (PK) and biodistribution of the therapeutic cargo, (2) solubilize hydrophobic 
drugs, (3) protect the drug from the extracellular environment and (4) guide the therapeutic cargo 
across existing extra- and intracellular barriers. Both low molecular weight chemotherapeutics, but 
especially membrane-impermeable macromolecular drugs (e.g. nucleic acids and proteins) require 
nanocarriers to enhance their delivery across biological membranes. Unfortunately, many synthetic 
nanoparticles (including lipid- and polymer-based nanoparticles) demonstrate insufficient in vivo 
targeting to extrahepatic tissues and fail to merge (intracellular) drug delivery efficacy with 
biocompatibility [108]. Since the identification of EVs as nature’s own intercellular 
communication tools, it is hypothesized that their Darwinian optimization could outperform 
conventional synthetic nanomedicines [109]. Indeed, EVs are believed to encompass many 
interesting features for drug delivery: (1) a proteo-lipid architecture that protects the encapsulated 
cargo, (2) their nanosize and specific composition minimizes recognition by the mononuclear 
phagocyte system (MPS) [110], (3) their patient self-derived nature mitigates activation of the 
adaptive immune system, (4) they contain specific lipids that help stabilize the vesicles in the blood 
circulation (e.g. GM3, sphingomyelin and cholesterol) and stimulate membrane fusion [51, 111] 
as well as surface proteins that have likewise been linked to membrane fusion in cell-cell and virus-
cell interactions (e.g. CD9, CD81) [112, 113] and finally (5) EVs seem to possess intrinsic cell and 
tissue targeting properties [114]. 
2.2.2. Extracellular behavior of EVs 
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One of the main motivations to incorporate drugs into nanocarriers is to modulate their 
biodistribution and tissue targeting. Free drugs are often rapidly cleared from the body and show 
poor tissue selectivity, which can in part be remedied by their formulation into nanomedicines. 
Unfortunately, without appropriate surface modification (e.g. PEGylation), they are easily 
recognized by the MPS and rapidly cleared from the blood circulation, leading to predominant 
sequestration by liver and spleen and limiting extravasation in other tissues of interest. As EVs are 
abundantly present and stable in the blood circulation, it was speculated that EVs could have longer 
circulation times and mediate drug targeting to extrahepatic and non-lymphoid tissues. However, 
reports studying the PK of IV injected EVs described short half-lives  (~2 minutes [115, 116] and 
~20 minutes [117]) with predominant uptake by liver, lung, kidney and spleen, thus closely 
resembling the biodistribution of synthetic liposomes [70, 118, 119]. The elimination after IV 
injection occurs via hepatic and renal routes [117] in which MPS-associated macrophages seem to 
play a key role [118]. It is conceivable that this recognition is in part mediated by the exposure of 
PS at the external side of EV (subtypes) [120, 121]. It is of note that in these studies tumor- or HEK 
293T-derived EVs have been used. For immature DC-derived EVs it was reported that they carry 
surface proteins (i.e. CD55 and CD59) inhibiting complement-mediated clearance [122]. 
Additionally, Whitehead et al. showed that EVs derived from malignant cells were far more prone 
to complement activation compared to non-malignant cells, which might help to explain some of 
the reported PK data [123]. Furthermore, also the selected purification protocol or the transfer of 
allogeneic EVs can potentially influence the EV’s PK profile [70]. 
Despite the intrinsic targeting to APCs and limited circulation time often reported for EVs, it 
appears that a certain fraction is still able to home to alternative organs and tissues. For instance, it 
was shown by Hoshino et al. that the integrins present on the surface of tumor-derived EVs 
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determined the organs/cell types that are preferentially targeted [114]. Such observations 
rationalize the engineering of EVs with specific targeting moieties to enhance tissue or cell specific 
homing. One of the first engineered EVs was reported by Alvarez-Erviti et al. who equipped EVs 
from immature DCs with a Lamp2b-RVG targeting peptide, via genetic engineering of the producer 
cell with the respective plasmid construct, to enable delivery of siRNA across the blood brain 
barrier (BBB) [124]. The same targeting ligand was also used to shuttle liposomes over the BBB 
for the delivery of siRNA [125]. The BBB targeting enhancement was later quantified by 
Wiklander et al. to be around two-fold [119]. Nonetheless, the majority of the vesicles was still 
present in MPS-associated tissues (i.e. liver, spleen and lung) [119]. The fact that targeting ligands 
are providing modest benefits is likely the result of the short circulation time. On the other hand, 
the partial degradation of the RVG targeting peptide during EV formation might also contribute to 
this observation. Indeed, Hung et al. showed that when fusing a targeting peptide to the Lamp2b 
protein (a protein inherently present on the EV surface) it should be equipped with a glycosylation 
site to protect it against protease degradation by the producing cell. The unprotected Lamp2b-RVG 
targeting construct showed only marginally improved internalization by N2A cells bearing the 
nicotinic acetylcholine receptor compared to non-targeted EVs due to peptide degradation [126]. 
In analogy with reports on synthetic liposomes, efforts to simultaneously enhance the circulation 
time and confer specific targeting properties have also been explored for EVs. For instance, 
hydrophilic PEG chains were inserted in the EV lipid bilayer carrying targeting nanobodies at their 
distal end to both shield the EV surface from off-target interactions (leading to a prolonged 
circulation time) yet allow specific interactions with a targeted receptor [127, 128]. However, such 
approaches greatly alter the composition and behavior of EVs, both in the extracellular 
environment as well as following intracellular uptake, and the question is raised to what extent 
these approaches are advantageous over synthetic drug-loaded nanocarriers.  
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The ability to cross the BBB is an interesting and often referred to feature attributed to EVs. 
Although the RVG-targeting ligand associated to the EV surface in the previously mentioned 
studies likely plays a potentiating role [124], EVs derived from unmodified hematopoietic cells 
were also shown to cross the BBB. This event was reported to be rare, yet occurs more frequently 
under peripheral inflammatory conditions [129]. The mechanism behind this process remains to be 
elucidated. One hypothesis is based on transcytosis in which EVs are taken up by (apical) 
endocytosis by endothelial cells and are again released at the basolateral side following exocytosis 
[130]. A recent study compared four types of EVs derived from different brain cells (i.e. brain 
endothelial cells (bEND.3), glioblastoma A-172 cells, neural glioblastoma U87 cells and 
neuroectodermal tumor PFSK-1 cells) for their ability to deliver cytotoxic drugs over the BBB in 
an embryo zebrafish model. Only the bEND.3derived EVs were able to transfer their cargo into the 
brain, underscoring the existence of EV specificity [131]. 
Besides transferring cargo over the BBB, tumor targeting is another therapeutic application for 
which nanomedicines can provide a clear benefit. For this purpose, nanomedicines typically rely 
on the enhanced permeation and retention (EPR) effect to extravasate and accumulate in the tumor 
mass. Based on their small size, it is conceivable that EVs can also exploit this effect for anti-
cancer treatment. However, such passive targeting of EVs to tumors gave rise to contradictory 
results. Smyth et al. IV injected EVs (60 µg) derived from the tumor itself but found very little 
amount in the tumor tissue (4T1 breast cancer and PC3 prostate cancer cells) compared to liver and 
spleen [118]. In contrast, Lai et al. found a marked signal of HEK-derived EVs (100 µg) in the 
tumor (Gli36 glioblastoma) alongside with the liver and spleen [117]. An example of successful 
tumor targeting by modified EVs was reported by Ohno et al. who observed a three-fold 
enhancement in the tumor tissue (HCC70 hepatocellular carcinoma) using EGFR-targeted (via the 
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GE11 peptide) EVs [132]. Comparable results were obtained with iRGD equipped EVs that bind 
to v3 integrins in tumor tissue. Importantly, these vesicles, when loaded with doxorubicin, 
strongly reduced tumor growth in a MDA-MB-231 breast cancer cell model [133]. Inspiration for 
targeting is often obtained from viruses. For instance, HEK293-derived EVs have been modified 
with gp350 (i.e. a ligand for CD21 expressed on B cells and a component of the Epstein-bar virus 
(EBV) envelope), conferring the viral tropism to EVs for normal and leukemic B cell targeting 
[134]. 
Finally, altering the PK of EVs can also be done by changing the route of administration. Indeed, 
Wiklander et al. compared IV, SC and IP injection of HEK293T EVs showing a clear difference 
in biodistribution [119]. After footpad injection accumulation of EVs in the lymph nodes was 
reported [135, 136] and intranasal application showed an accumulation in the brain [137, 138] in 
which the delivered anti-inflammatory cargo (i.e. curcumin) could still be detected up to 12 hours 
after administration [137]. 
2.2.3. Intracellular trafficking of EVs 
Especially when considering EVs for delivery of macromolecular therapeutics, which require 
delivery into the cell’s cytoplasm (e.g. miRNA, mRNA) or even nucleus (e.g. pDNA), the ability 
of EVs to shuttle their cargo over the cellular barriers is of key importance. 
Nanoparticles can employ distinct endocytic uptake pathways to gain access to cells. Numerous 
studies have investigated the mechanism(s) by which EVs are associated to and subsequently 
internalized by cells. Many different types of surface molecules, both EV- and cell-associated, have 
been identified as being involved in EV-cell contact (i.e. tetraspanins, integrins, proteoglycans and 
lectins) as comprehensively reviewed by Mulcahy et al. [139]. These interactions, possibly 
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preceded by surfing onto filopodia according to recent observations [140], mostly lead to cell 
uptake via one of the common endocytosis pathways (i.e. clathrin- and caveolin-dependent 
endocytosis, lipid raft-mediated endocytosis, macropinocytosis or phagocytosis) [105, 139]. It is 
also interesting to note that inhibition of a given pathway is almost never able to completely 
abrogate the EV uptake, hinting toward the involvement of multiple uptake mechanisms and/or 
reflecting EV heterogeneity [139]. In this regard, it would be an interesting strategy to also link the 
effect of uptake inhibitors to the induced phenotypical changes in recipient cells as this would help 
to elucidate which specific uptake pathway(s) leads to functional cellular release of the EV cargo. 
As the interaction of EVs with cells likely involves multivalent ligand-receptor binding, it is 
reasonable to assume that they finally are trafficked to lysosomes for degradation [140]. Hence, 
delivery of drugs into the cell cytoplasm will require a mechanism that allows the EV cargo to 
escape the endolysosomal compartment. Also for synthetic nanomedicines the endolysosomal 
entrapment is one of the major hurdles for efficient cellular delivery of membrane impermeable 
drugs. The delivery efficiency of nanomedicines hinges on strategies to cross the endosomal 
barrier, such as the so-called proton sponge effect and/or lipid bilayer fusion [141]. As many of the 
effects mediated by EVs have been attributed to the functional delivery of miRNA and mRNAs, 
[87] this implies that (subtypes of) EVs might contain built-in mechanisms to stimulate endosomal 
escape. The most plausible theory describes back-fusion of internalized EVs with the endosomal 
membrane, thus releasing their content in the cytoplasm (figure 2). However, few reports directly 
demonstrated EV fusion with plasma-and/or endosomal membranes. Some studies labeled EVs 
with a self-quenching dye after which they were incubated with cells. An enhancement of 
fluorescence was indicative of dye dequenching and hence fusion of (a fraction of) EVs with 
cellular membranes [51, 91]. Alternatively, luciferin containing EVs were able to evoke a 
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luminescent signal after interaction with luciferase expressing cells, suggesting cytosolic delivery 
of the EV luminal cargo [91]. Whether this intracellular delivery process is linked to a particular 
receptor-ligand interaction or requires a specific proteolipid composition is currently unknown.  
Alternative to relying on the intrinsic EV properties to obtain functional delivery, EVs have been 
modified with delivery-enhancing peptides. Temchura et al. decorated antigen-loaded EVs with a 
vesicular stomatitis virus G (VSV-G) protein to stimulate the cross-presentation of these antigens 
in recipient DCs [142]. The VSV-G protein promotes the fusion of lipid membranes at lower pH 
(i.e. ~6) and can thus drive destabilization of the endosomal/phagosomal membrane following 
internalization [143]. These authors showed that the VSV-G protein stimulated MHC I mediated 
antigen presentation and elicited an antigen-specific CD8+ T cell response [142]. The previously 
mentioned RVG targeting ligand [119, 144, 145] and iRGD [133, 146] have also been reported to 
have membrane-destabilizing properties, possibly contributing to enhanced cytoplasmic delivery 
of the encapsulated cargo.  
It is of note that not for all phenotypical effects EV internalization is necessary. Physiological 
effects attributed to EVs can be based on proteins and lipids present on the surface of EVs 
interacting with ligands on the target cell’s surface triggering intracellular signaling pathways 
(figure 2) [88, 147-149] or via enzymatic activity present inside or on the surface of EVs [150]. 
2.2.4. Loading EVs with a therapeutic cargo 
The clinical implementation of EVs as a viable drug delivery platform will require optimized 
methods allowing efficient loading with the drug of choice. As already indicated above, EVs have 
been evaluated as a drug delivery vehicle for a vast diversity of therapeutic cargos, including both 
small molecules (e.g. doxorubicin, curcumin,…) and macromolecules (i.e. RNA, DNA and 
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proteins). The strategies to incorporate these drugs into EVs can generally be divided in pre-and 
post-formation approaches [151]. In the former case, the therapeutic cargo is first loaded into the 
respective producer cell followed by its packaging into EVs during their biogenesis. For the latter 
approach, EVs are first purified from the producer cell’s conditioned culture medium after which 
they are loaded with the therapeutic cargo via one of the methods represented in table 2. 
In a pre-formation loading approach the endogenous sorting machinery of the cell is used to load 
the cargo into the EVs (table 3). Loading of specific nucleic acids (siRNAs, miRNAs, mRNAs) 
into EVs can be accomplished by transfection of the producer cell with the respective cargo (e.g. 
miRNA) by lipofection [52]. A comparable approach, by incubating the producer cell (i.e. MSCs) 
with free paclitaxel, has also been evaluated. The paclitaxel-loaded EVs that were secreted by the 
MSCs induced an anti-proliferative effect on in vitro cultured adenocarcinoma cells [152]. 
Alternatively, the RNA of interest can be expressed in the producer cell via a plasmid vector 
encoding for the respective nucleic acid therapeutic (e.g. miRNA [153], siRNA [154], mRNA 
[155]). Unfortunately, such pre-formation loading approaches typically show limited loading 
efficiency and should be optimized for each selected producer cell type and cargo. In addition, one 
needs to anticipate that the selected cargo can influence the producer cell’s functionality and 
viability, hence impairing the loading process. Although still largely elusive, our expanding 
knowledge on the endogenous cargo sorting machinery can be exploited to increase the drug 
loading efficiency by modifying the therapeutic cargo. In this respect, proteins can be equipped 
with a plasma membrane anchoring and oligomerization domain to stimulate EV loading [156]. 
Alternatively, proteins can also be sorted into EVs by creating a fusion construct containing the 
protein of interest linked to a protein that is inherently associated to EVs as has been done for EV 
targeting purposes (section 2.2.2.) [144, 157] or to fluorescently label EVs (e.g. CD63-GFP) [158]. 
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Likewise, also for nucleic acids, evidence is mounting that by altering the nucleotide sequence also 
the sorting efficiency can be modulated. Bolukbasi et al. identified a specific sequence in the 3’-
UTR region of mRNA strands that promotes its accumulation in glioblastoma-derived EVs. This 
~25 nucleotide sequence contained a miR-1289 binding region and a CUGCC sequence. 
Incorporation of this so-called ‘zip-sequence’ in the 3’-UTR of a mRNA strand increased its 
packaging into EVs two-fold compared to the unmodified sequence. This enrichment could even 
be further enhanced when miR-1289 was overexpressed in the producing cell [39]. Regarding 
miRNA sorting, Koppers-lalic et al. discovered that 3’-uridylated miRNAs are enriched in human 
B cell-derived EVs [45]. Villarroya-Beltri and colleagues showed that miRNAs containing a 
GGAG sequence were overrepresented in primary T lymphoblast EVs. They suggest that this 
sequence is selectively recognized by the RNA binding protein heterogeneous nuclear 
ribonucleoproteins A2/B1 (hnRNPA2B1) and subsequently drives incorporation into EVs [38]. 
However, these sequences could not be retrieved in miRNAs accumulating in colorectal cancer-
derived EVs, implying the existence of distinct sorting pathways [159]. Although progress is being 
made, in general these sorting mechanisms remain vaguely defined to date. 
In addition to the above mentioned loading approaches for small molecules and macromolecules, 
viral capsids (i.e. AAV) have been loaded in EVs thus creating so-called vexosomes. These hybrid 
vesicles are composed of viral particles coated with or associated to EVs. Vexosomes aim to merge 
the efficient transfection capabilities of the AAV and the immune-shielding properties of EVs to 
produce a potentially efficient and biocompatible delivery vehicle [160]. Indeed, EVs appear to 
protect AAVs from adaptive immune detection. Hence, vexosomes outperformed uncoated AAVs 
regarding in vivo transfection efficiency in the presence of neutralizing antibodies [161]. Moreover, 
the coating with EV membranes potentiated the AAV’s ability to cross the BBB. The mechanism 
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behind this phenomenon is currently unknown [162]. Overall, the above mentioned features denote 
that this hybrid system is a potentially interesting therapeutic tool, combining the best of two 
worlds. 
On the other hand, post-formation loading approaches attempt to load drugs in isolated and purified 
EVs. In this regard, the most frequently reported method, especially for hydrophilic membrane-
impermeable components, is electroporation (EP). EP is traditionally used to introduce nucleic 
acids in cells using high-voltage electric pulses to create transient pores in the plasma membrane 
[163]. The group of Matthew Wood reported the first successful EP of siRNA into DC-derived 
EVs allowing functional delivery across the BBB in a mouse model of Alzheimer’s disease [144]. 
Following this pioneering report, other research groups have shown comparable results for loading 
siRNA and even DNA strands up to a 1000 bp into EVs [164-168]. Besides nucleic acids, 5 nm 
superparamagnetic iron oxide particles and large proteins have been loaded in purified EVs using 
EP (table 2). Despite the fact that different groups reported efficient cargo loading using this 
approach, the technique is under debate as it was shown that EP can induce the formation of large 
aggregates that co-precipitate siRNA and hence greatly overestimates the actual loading efficiency 
[169]. Since the publication of this report, several groups have tried to prevent this aggregate 
formation through the use of chelating agents (e.g. EDTA) [166] or membrane stabilizers (e.g. 
trehalose) [170, 171]. Nonetheless, even if transient pores would be formed in the EV membrane 
and aggregation can be prevented, given that EP likely relies on passive loading it can only be 
efficient in extremely concentrated EV isolates [169]. Other post-formation strategies that are being 
explored for hydrophilic molecules are also based on transiently destabilizing the EV membrane, 
including repeated freeze-thaw cycles, sonication, extrusion or saponin treatment (table 2). These 
techniques have been evaluated for both small molecules (i.e. porphyrins) [172] as well as 
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macromolecules (i.e. the 240 kDa catalase enzyme) [138]. It is important to note that for the former 
methods, the integrity of the EVs can be significantly compromised [138]. One report also suggests 
that antibody-coated EVs derived from B1a cells can interact with and take up miRNAs from the 
environment by simple co-incubation and subsequently shuttle it into cells. However, the 
mechanism behind this post-formation miRNA loading as well as the generality of this loading 
approach remain to be elucidated  [173]. 
For hydrophobic membrane-permeable molecules, simple co-incubation at ambient or elevated 
temperature are often sufficient to load EVs [131, 174]. Indeed, EVs derived from EL4 cells 
incubated with curcumin at room temperature were, after intranasal delivery, able to significantly 
delay brain tumor growth in the GL26 mice tumor model [137]. Curcumin-loaded plant EVs for 
example are currently under clinical evaluation in colon cancer (NCT01294072). An overview of 
other small molecules loaded via co-incubation is given in table 2. However, leakage of these 
therapeutics out of the vesicles in biological fluids (e.g. plasma) can limit their practicality. 
As long as the fundaments of EV biogenesis and cargo sorting are not clear, pre-formation methods 
will suffer from limited efficiency. Indeed, when comparing both loading strategies for paclitaxel, 
the post-formation method yields ~21 mg/g EV [175] and ~7.3 mg/g EV [131] compared to ~2 
µg/g EV [152] for the pre-formation method. Overall, loading hydrophobic small molecules in EVs 
is more straightforward and efficient. For post-formation loading of hydrophilic compounds, 
especially macromolecules, important progress still has to be made before efficient clinical 
application of EVs as drug delivery vehicles can be envisioned. In this respect, a generic post-
formation loading strategy for siRNA was recently developed by exploiting the efficient 
hydrophobic interaction between cholesterol-conjugated siRNA (chol-siRNA) and the EV 
proteolipid surface [176]. Unfortunately, the EVs used in this study were not able to escape the 
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endolysosomal degradation pathway and hence failed to functionally deliver the siRNA in contrast 
to anionic fusogenic liposomes that were equally loaded with chol-siRNA. Moreover, the 
endogenously present miRNAs were not able to silence their respective target proteins which is in 
accordance with recent reports describing that (1) even the most abundant miRNAs found in EVs 
are secreted at a (low) ratio of 1 molecule per 100 vesicles [46, 177]  and (2) internalized EVs are 
typically trafficked toward the lysosomes [140, 178]. Although this particular combination of EVs 
and recipient cells did not lead to successful EV-mediated drug delivery [176], it does not invalidate 
the concept of EVs as drug carriers as their interaction with cells might be highly specific. 
Therefore, a more in-depth biological understanding of the EV’s delivery mechanism is urgently 
required, including cell type specificity, cellular uptake mechanism, intracellular trafficking and 
cellular cargo delivery.. 
2.2.5. Producer cell source selection 
The choice of an adequate producing cell when aiming to exploit EVs as a drug delivery vehicle is 
of pivotal importance as it will define the PK behavior (i.e. the stability in the blood circulation 
and organotropism; section 2.2.2.) and the intrinsic biological effect (both physiological and 
pathological; section 2.1.) of the EV carrier. It has been suggested that MSCs form a sustainable 
source of EVs. MSCs produce high quantities of EVs and neither the EV yield nor their 
composition is altered by immortalizing the producer cell. Moreover, MSCs are known for their 
low immunogenicity making allogeneic applications possible [99, 179] (NCT02138331). 
However, it is also shown that MSC-derived EVs stimulate tumor vascularization and tumor 
growth, which might induce undesirable off-target effects [180]. Besides MSCs, immature DCs 
have also been proposed as an interesting EV source due to their low immunogenicity, 
immunosuppressive effects and the ease with which autologous sources can be obtained [109, 181].  
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As the field is moving closer to clinical applications, the concept of high vesicle yield with minimal 
production costs is of increasing importance. In this respect, research groups have started to focus 
on alternative sources of EVs. Grapefruit- and milk-derived EVs have been investigated as drug 
delivery vehicles [182-184]. Additionally, the idea of creating EV mimicking vesicles, e.g. by 
means of sequential extrusion of cells through micro-and nanoporous filters [185, 186] or by 
mixing synthetic components attempting to reproduce the most important EV characteristics [79, 
187], is gaining interest. However, the latter approach is difficult to implement as long as the 
knowledge on which components are essential for EV functionality is lacking or incomplete.  
2.3.EVs as vaccination platform 
The first therapeutic application of EVs was based on the use of DC-derived EVs as a surrogate for 
DC-based anticancer vaccination, [10] as APC-derived EVs harbor both (antigen-loaded) MHC I 
and II as well as the necessary co-stimulatory factors, to directly trigger (CD8+ and CD4+) T cell 
activation [9, 47]. However, in vivo, DC-derived EVs likely interact first with endogenous DCs 
(via cell surface adhesion or intracellular processing), transferring their antigens to endogenous 
APCs and augmenting T cell activation [188, 189]. The use of DC-derived EVs for cancer 
immunotherapy has already been evaluated in phase I clinical trials for both melanoma [13] and 
non-small-cell lung carcinoma (NSCLC) [190]. Although DC-derived EVs exhibited an excellent 
safety profile, the therapeutic effects were limited with no substantial CD8+ T cell response. 
Nonetheless, pre-clinical studies have shown that co-delivery of adjuvants could vastly improve 
the evoked immune response. In this respect, Chaput et al. reported the combination of DC-derived 
EVs with CpG (a TLR3 agonist) [191], Guo and colleagues combined DC-derived EVs with 
another TLR3 agonist, i.e. polyinosinic-polycytidylic acid (poly(I:C))  and cyclophosphamide 
[192] and Gehrmann et al. associated -galactosylceramide (a iNKT stimulatory factor) to antigen-
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loaded DC-derived EVs, which induced a potent NK,  T-cell innate immune response and 
enabled proliferation of antigen-specific T and B cells [193]. Currently, a phase II clinical trial in 
NSCLC patients is evaluating the combination of cyclophosphamide with DC-derived EVs (pulsed 
with a range of antigens and INF-) that showed an improved immune stimulatory capacity in pre-
clinical studies [194] (NCT01159288). 
As pointed out above (section 1.2.), EVs derived from cancerous cells have shown to carry a panel 
of known (e.g. CEA, GP100, HER2, melan-A, PSMA) [32, 195] and likely to date unknown tumor 
antigens. This is not only of interest from a diagnostic point of view but also makes tumor-derived 
EVs, which have shown to outperform free antigens [193, 196] and whole tumor lysate [197, 198], 
an attractive candidate to evaluate as a cell-free vaccine. Building on these promising observations, 
a clinical trial has been conducted using EVs isolated from ascites fluid. Unfortunately, similar to 
the DC-derived EVs, the effect of unmodified EVs was unsatisfactory. However, when co-injecting 
GM-CSF as adjuvant, a pronounced anti-tumor cytotoxic T lymphocyte response was induced 
[199]. As for DC-derived EVs, tumor-derived EVs in preclinical reports benefit from the indirect 
antigen presentation by endogenous APCs. This can be stimulated by combining tumor-derived 
EVs with synthetic adjuvants [200] or using EVs derived from (genetically) modified tumor cells 
to enhance the presence of adjuvant-like components (e.g. heat treatment to enhance hsp70 in 
tumor-derived EVs [201] or genetically engineer tumor cells to release IL18 [202] or IL12 [203] 
in EVs). It appears that for both strategies of EV-mediated anticancer vaccination, vesicles have to 
be modified to enhance their immune stimulatory effect.  
Despite the multitude of reports showing the potential of (adjuvant-modified) tumor-derived EVs 
as antigen delivery vehicles, caution should be taken as there is mounting evidence that tumor-
derived EVs exhibit immunosuppressive characteristics. Indeed, besides antigens, the presence and 
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functional transfer of fasL [204], TGF-[205] and NKG2D ligand [206] by tumor-derived EVs 
was also reported, all of which can blunt the activity of effector T cells. Moreover, some tumor-
derived EVs are considered pro-metastatic via niche formation [114, 207], angiogenesis 
stimulation and extracellular matrix degradation (e.g. via presence of metalloproteinases) [208]. 
Additionally, providing a good source for tumor-derived EVs in a clinical context is not evident. 
The most elegant, easy accessible source is ascites fluid. However, only few tumors entail the 
accumulation of EVs in this biofluid [32]. Alternatively, EV mimics can be produced from cancer 
cell biopsies via sonication. Whether these vesicles have the same ability as natural EVs to evoke 
an anti-tumor immune response is not known [209]. To make use of tumor-antigen bearing EVs 
without the negative characteristics of tumor-derived EVs, a DNA vaccine (delivered via an 
adenoviral vector or EP) was developed that encodes a fusion protein comprising (the extracellular 
part of) a known tumor-antigen and an EV-associated protein (C1C2 domain of lactadherin or the 
gag protein). Expression of this fusion construct shuttles the associated antigens to the surface or 
lumen of secreted EVs, respectively [157, 210]. Nevertheless, this technology is limited to well-
characterized antigens and would likely benefit from an additional immune modulator. Excellent 
dedicated reviews on the interplay between EVs and the immune system can be found in the 
literature [211]. 
Next to eukaryotic cells, also prokaryotic cells release vesicles in the extracellular environment, 
which are termed outer membrane vesicles (OMVs). It is interesting to note that the use of OMVs 
as vaccination tool against infectious diseases is currently the most advanced therapeutic 
application of EVs with different ongoing and completed clinical trials (up to phase IIIb; e.g. 
NCT01423084, NCT01478347, NCT02446743, …) and a selection of OMVs that have already 
reached market approval (e.g. Bexsero® and MenBvac® for serogroup B meningococcal disease). 
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For a comprehensive discussion on the use of OMVs as vaccination technology the reader is 
referred to Van Der Pol et al. [212]. 
3. EV Biomarker mining  
3.1. An introduction to biomarkers 
A biomarker can be defined as an objectively measured characteristic that indicates the medical 
state of the patient. Biomarkers can assist clinicians in making a reliable diagnosis and can be used 
as a clinical endpoint surrogate in clinical trials. For both applications it is critical that the 
correlation between disease and biomarker is well characterized and validated [213].  
A reliable biomarker has to fulfill a number of prerequisites. First, a biomarker needs to be specific, 
a feature with which many known biomarkers struggle (e.g. prostate specific antigen ( PSA) often 
gives false positives for benign prostate hypertrophy) [214]. Also, it is of critical importance that a 
biomarker is robust and valid meaning that under all given conditions a correlation exists between 
the biomarker and the disease. In this respect it is important to have a clear understanding of the 
role of the biomarker in the pathophysiology of the disease. Ideally, biomarkers should be 
predictive, indicating that the quantity of the biomarker can be (positively or negatively) correlated 
with the severity of the disease. Furthermore, it is of interest that the biomarker is easy accessible, 
thereby minimizing the burden for the patient. Finally, the sensitivity of the biomarker (or 
diagnostic assay to quantify the biomarker) will determine the extent to which early diagnosis is 
feasible [213]. 
Parallel with the emergence of personalized medicine, the importance of adequate biomarkers is 
further increasing. Personalized medicine can provide a significant benefit for diseases exhibiting 
a strong inter-patient pheno- and/or genotype heterogeneity as is the case for many tumors [215]. 
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Therapies that are tailored towards a specific phenotype (e.g. Herceptin® for Her2 positive breast 
cancer patients) are often developed in parallel with a biomarker assay, which enables the clinician 
to select patients who are eligible for the respective therapy [216]. 
3.2.EVs as biomarker 
EVs can be regarded as a stable and easy accessible fingerprint of the parent cell [217]. Indeed, the 
EV composition will depend on the type and even status of the producer cell [218, 219]. As EVs 
are easily secreted by the large majority of cell types in the human body, they can be retrieved from 
all bodily fluids [220]. EVs have been isolated from e.g. urine [11], plasma [26], semen [25], nasal 
secretion [24], breast milk [221], the aqueous humor of eyes [222], cerebrospinal fluid [223], 
peritoneal fluid [224], bronchoalveolar lavage [225]. Depending on the respective disease for 
which the biomarker is being developed, an accessible biofluid should be considered in which the 
EVs of interest are likely the most concentrated and a liquid biopsy can be easily obtained. 
Moreover, due to their liposome-like architecture, EVs protect their cargo against the harsh 
environment present in many of these media providing a more stable, hence reliable biomarker 
source compared to naked RNA or proteins in e.g. blood. 
EVs have been linked to a plethora of (patho)physiological processes. They are involved in 
maintaining cellular homeostasis but have also been linked to for example cancer progression. 
Glioblastoma-derived EVs have shown the ability to spread oncogenic transformation by 
transferring the oncogenic form of the epidermal growth factor receptor (EGFRvIII) to surrounding 
cells [226]. These EGFRvIII expressing vesicles were also detected in the serum of 7 out of 25 
glioblastoma patients and have been proposed as biomarker source [12]. Additionally, tumor-
derived EVs have shown the ability to promote cancer growth by inhibiting cancer-specific 
immune recognition (section 2.3.) [88, 227]. Moreover, EVs are also involved in the metastasis of 
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tumor cells as they are believed to prepare a pre-metastatic niche at a secondary tissue or organ 
(the seed-and-soil hypothesis) [114, 135, 207]. The fact that EVs play such an important role in the 
process of tumor formation strengthens the validity and robustness of their use as biomarker in 
cancer detection. Besides cancer, EVs are also exploited by viral particles (e.g. HIV, Epstein-bar, 
hepatitis C) to mediate their spread, making EVs valuable tools to detect viral diseases as well 
[228]. Furthermore, EVs are associated with neurological, metabolic, cardiovascular and kidney 
conditions and are therefore also proposed as biomarkers for these diseases [229-231]. 
In the literature many different clinical samples have been shown to contain EV-associated 
biomarkers with diagnostic/prognostic value or disease monitoring potential. In this respect, the 
EV concentration present in serum of tumor-bearing patients was shown to be increased compared 
to healthy controls [217, 232-235]. The EV protein abundance also has prognostic value as it was 
observed that patients with stage III melanoma with a high EV-associated TYRP2 protein burden 
showed increased risk of disease progression [207]. Moreover, following resection of the primary 
tumor, the EV concentration markedly decreased indicating its correlation with tumor presence 
[235]. However, relying solely on EV concentration lacks specificity as the same observation was 
made for distinct cancer types [217, 232-235] and, importantly, for non-disease stimuli (e.g. 
physical exercise [236]). Furthermore, early diagnosis of many cancers will not be possible. 
Therefore, it is of outstanding interest to look in more detail to the EV cargo (i.e. proteins, miRNA, 
mRNA,…) as they provide an easy accessible window to monitor the status of the respective 
producer cell (section 1.2.). In this respect, the exploitation of comparative omic-studies is 
fundamental for the detection of new biomarkers. For instance, it was revealed that a panel of eight 
EV-associated proteins were upregulated in the urine of patients with bladder cancer compared to 
healthy subjects [237]. Likewise, miRNA profiling of plasma-derived EVs identified a panel of 
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four tumor-specific miRNAs of potential use in a screening test for lung carcinoma [238]. A 
comprehensive review on this topic was recently issued by An and colleagues [239]. 
Isolating EVs from a liquid biopsy prior to molecular analysis enhances the sensitivity (compared 
to whole blood/urine analysis) as highly abundant serum/plasma proteins (e.g. albumin) and urine 
proteins (e.g. Tamm–Horsfall glycoprotein) are removed [240]. It is estimated that less than 0.01% 
of the proteins present in plasma are EV associated [241]. It is important to realize that in biological 
fluids, in general the vast majority of EVs are derived from healthy cells. In this respect it is 
reasonable to speculate that the sensitivity and specificity can be further enhanced through isolation 
of cell- or tissue-specific EVs prior to a biomarker assay. Such an approach was explored by Taylor 
and colleague who isolated EVs from plasma by antibody-based capturing (using anti-EPCAM) 
and subsequently analyzed the miRNA profile in this tumor EV enriched population. They could 
show that the miRNA profile closely resembled that of the original primary tumor cell. The 
combination of EPCAM-based EV capture and downstream miRNA quantification could hence be 
used to distinguish between healthy patients and patients at different stages of ovarian cancer [233]. 
Another example of the importance of an upstream EV selection was provided by Shi et al. who 
measured -synuclein levels in plasma of healthy individuals and patients suffering from 
Parkinson’s disease. When analyzing -synuclein levels in plasma using the total EV population, 
no significant difference could be observed between both groups. However, when the 
quantification was performed on plasma EVs positive for L1 cellular adhesion molecule (L1CAM), 
which is primarily expressed in the central nervous system, the -synuclein levels were 
significantly enhanced in Parkinson’s disease patients [242]. However, specific cancer markers are 
not always known or present on the EV surface. Additionally, population assays neglect an 
additional level of complexity conferred by the specific composition of individual vesicles, which 
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can provide relevant supplementary information. Therefore, techniques that allow analysis on the 
single vesicle level are of great interest [243]. However, for diagnostic purposes such an approach 
will require screening of large amounts of vesicles as ‘diseased’ EVs are rare among the total 
isolated EV population. One promising approach relies on modifying flow cytometry 
equipment/protocols to detect single, nanosized EVs [244-246]. However, to date FACS is not able 
to detect the lower size range of EVs and requires antibodies (and hence also knowledge of a 
particular disease marker) to phenotype EVs. Unfortunately, antibody-independent techniques that 
combine single vesicle sensitivity and high acquisition speed are scarce. One alternative strategy 
recently explored relies on surface enhanced Raman spectroscopy (SERS), which provides a 
quantitative molecular fingerprint of single EVs with a minimal acquisition time (500 ms) (figure 
3). Based on the obtained Raman spectra, EVs derived from erythrocytes and melanoma cancer 
cells could be distinguished [247]. 
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Figure 3. Surface Enhanced Raman Spectroscopy (SERS)  characterization of 
single EVs. [A] Enhancement of the Raman signal was obtained by decorating 
individual EVs with a AuNP-based nanoplasmonic SERS substrate. Raman spectra 
were recorded by moving the focal volume through the sample. The location of a 
AuNP-coated EV was determined by Rayleigh scattering (as depicted on the right 
insert of panel A, image 2). Using this approach, SERS spectra were obtained from 
[B] B16F10 melanoma-derived EVs and [C] erythrocyte-derived EVs. Red arrows 
in the displayed representative spectra originate from the AuNP coating material, 
while green arrows mark EV-related peaks. Partial least squares discriminant 
analysis on the obtained spectra allowed to distinguish between both vesicle types 
in a mixture, demonstrating the potential of single vesicle SERS fingerprinting in a 
diagnostic context. Reproduced with permission from ref.[247]. Copyright 2016 
Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. 
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3.3.Perspectives  
The wide-spread interest from both academia and industry in exploiting EVs in a diagnostic context 
is evident from ongoing and completed clinical trials (NCT02702856, NCT01779583, 
NCT02147418, NCT01860118, NCT02439008, NCT02464930, NCT02662621) and extensive 
investments from the pharmaceutical industry (e.g. Exosomedx, Exosome sciences, Codiak 
Biosciences, Hansabiomed, etc.). These investments are accompanied by a multitude of filed 
patents claiming technical solutions for the purification and/or readout of this new type of 
biomarker source. A first diagnostic test (the ExoDx Lung (ALK) by Exosome Diagnostics), based 
on detecting a specific NSCLC-associated mutation present in exosomal RNA became 
commercially available at the beginning of 2016 [248].  
Nonetheless, various issues still hamper the full exploitation of their biomarker potential. For 
instance, the lack of standardized purification protocols counteracts reproducibility and strongly 
influences biomarker identification. Due to this lack of consensus, to date no specialized EV-
biobanks, where a specific biofluid/biopsy sample can be correlated to the patient’s medical record, 
are established [249]. Moreover, elaborate purification protocols preclude fast screenings and 
hence restrain investigation and validation in large patient cohorts. Besides the purification 
protocol, also other parameters, among which the sample collection procedure (e.g. the type of 
anticoagulant during blood collection [250]), processing time and sample store conditions [65, 86] 
can influence the outcome of biomarker identification studies [251]. In response to this unmet need, 
an ISEV position paper was issued describing guidelines on how to handle different biological fluid 
samples and emphasizing the importance of a comprehensive experimental description to enhance 
reproducibility [252].  
4. General conclusion 
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Inspired by their involvement in many (patho)physiological processes and their role as nature’s 
own intercellular transport vehicles for biomolecules, a multitude of therapeutic and diagnostic 
applications have been explored for EVs.  
To date, EVs have been successfully exploited as biological nanocarriers for synthetic drugs 
ranging from small molecule chemotherapeutics to macromolecular siRNA, proteins and mRNA 
in various preclinical studies. However, clinical translation will essentially depend on substantial 
improvements in cost-effective EV isolation methods, improved drug loading techniques and more 
detailed knowledge on EV composition, heterogeneity and inherent biological effects. 
Additionally, a knowledgeable assessment of the value of EVs as drug delivery vehicles will 
require a direct comparison between EVs and current state-of-the-art synthetic and viral delivery 
vehicles.  
The complex composition of EVs conceivably correlates with off-target effects. On the other hand, 
this inherent complexity conferred by the many bioactive components associated to EVs enables 
them to induce potential beneficial effects likely challenging to mimic with therapeutic 
formulations containing a single drug. In this respect, MSC-derived EVs have been investigated in 
the field of regenerative medicine, auto-immune diseases and other inflammatory conditions as a 
safer alternative to whole cell therapeutics. EVs derived from both antigen-pulsed DC and tumor 
cells have been tested extensively for vaccination purposes. Despite the fact that the current clinical 
data show limited effect, pre-clinical reports indicate that modifications (e.g. co-delivery of an 
adjuvant) can further stimulate the evoked immune response. Nonetheless, it is important to note 
that safety concerns on the use of tumor-derived EVs are raised as many reports have linked EVs 
released by tumor cells to disease progression and metastasis. Here, ample attention should be 
given to further optimize EV purity and characterization protocols. 
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Finally, EVs have great potential to be harnessed in a diagnostic, prognostic and treatment 
monitoring context. EVs form a reliable and easily accessible window on the physiological status 
of the parent cell. They contain a vast amount of molecular information, which can be extracted by 
downstream proteomic, transcriptomic, miRNomic and lipidomic analysis, the feasibility of which 
has recently been underpinned by the first EV-based diagnostic test entering the US market. To 
galvanize further development of EVs as biomarkers, again fast, efficient and standardized 
purification protocols in combination with sensitive quantification methods will be essential. 
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Table 1. Overview of the most used EV isolation methods.
Method Principle of 
separation 
Purity Integrity Disadvantages Advantages
Ultracentrifugation 
(UC) 
Size and 
density  
Medium 
 
High shear forces might 
affect EV 
integrity/functionality  
Relatively long procedure (~4-5 
hours) 
The yield is drastically reduced 
when the viscosity of the 
samples is high (e.g. plasma > 
serum > celmedium > PBS) [67] 
Most used technique throughout the literature  
 
 
Density gradient 
UC / sucrose 
cushion UC 
Size and 
density 
High Mild forces Long procedure (~18 hours) 
Effect of the gradient  forming 
molecules on the EV 
functionality is unknown 
Previously used in clinical settings [13, 190, 199, 253] 
Precipitation Salting out 
EVs using a 
PEG/salt 
solution 
Low Mild forces 
 
Low purity 
The PEG chain might envelope 
the EVs, possibly interfering with 
their functionality 
Applicable for large volumes 
Experience from the viral field 
Previously used in a clinical setting (as an EV 
concentration step prior to UC) [99] 
Affinity capture Binding of EV 
surface 
components  
High Mild forces  
 
Expensive (if antibody based) 
EV elution might damage 
surface proteins and 
functionality 
This method has the highest potential to physically separate 
different EV (sub)populations. However, due to the lack of 
specific markers for EV subtypes to date, this method is 
most frequently applied in the diagnostic field 
Size exclusion 
chromatography 
(SEC) 
Size Medium to high Mild forces The final EV isolate is diluted Chromatographic methods (e.g. SEC and IEC) are often 
used in clinical settings (e.g. to purify monoclonal 
antibodies) 
Sequential 
filtration 
Size Unknown Risk of modifying the 
original EV architecture 
due to extrusion 
Sticking of EVs to the filter 
membrane lowers the yield 
Useful as a pre-process concentration step. Previously 
used for this purpose in clinical settings [13, 253] 
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Table 2. Post-formation loading of EVs 
Method Cargo Efficiency Remarks Ref 
EP:  
 M+ electrodes (400 V; 125 μF) 
 Buffer: OptiprepTM; neutral pH 
siRNA 25% of the total RNA The reported RNA exceeds 
maximal theoretical loading 
based on the total vesicular 
volume% and assumption 
that loading is a passive 
process [169] 
[124] 
EP:  
 M+ electrodes (150 V; 100 µF)  
 Buffer: Cytomix buffer 
siRNA 90% of the total number of 
beads carrying EVs is 
positive for siRNA 
 [168] 
EP:  
 M+ electrodes (400 V; 125 
μF) + polymer electrodes 
(variable settings) 
 Buffer: OptiprepTM; neutral 
pH, EDTA containing buffer, 
acidic pH 
siRNA No significant 
encapsulation 
Shows the formation of 
aggregates during the EP 
process and highlights the 
importance of adequate 
controls when using EP as a 
loading method. 
[169] 
EP miRNA No significant 
encapsulation reported 
 [132] 
EP: 
 M+ electrodes (0.75 kV/cm)  
 Buffer: Trehalose containing 
buffer  
5 nm 
superparamagnetic 
iron oxide 
nanoparticles 
0.40-0.45 µg iron/µg EV  [170] 
EP:  
 M+ electrodes  
 Buffer: PBS 
70 kDa Dextran / 
Saporin 
0.4% and 0.5% of the total 
dextran and saporin, 
respectively. 
Required Lipofectamine LTX 
and GALA fusogenic peptide 
for functional delivery 
[254] 
Co-incubation (T=37°C) miRNA (miR-150) N.R. Indirect proof of successful 
delivery is provided via 
restoration of the effect when 
using miR-150 knockout EVs 
[173] 
     
Co-incubation + 0.01% saponins, 
*freeze/thaw, *sonication, 
*extrusion 
Catalase (240 
kDa) 
~15 – 25% of the added 
catalase 
*Indicated technique entail 
significant alteration of the 
EV structure 
[138] 
     
Co-incubation (+ 0.01% saponins), 
hypotonic dialysis 
Porphyrins Up to ~2.5x1015 
molecules/EV 
 [172] 
EP: 
 M+ electrodes ( 350 V and 
150 μF) 
 Buffer: non-specified 
electroporation buffer 
Doxorubicin 20% of the added 
doxorubicin 
EVs equipped with a targeting 
ligand (i.e. iRGD associated 
to LAMP2) – non targeted 
EVs were not functional  
[133] 
Co-incubation (T=22°C – 5 min) Curcumin 2.9 µg/µg EVs IP injection [174] 
Co-incubation (T=22°C – 5 min) Cucumin / JSI-124  Intranasal administration [137] 
Co-incubation (T=37°C – 2 h) Doxorubicin / 
paclitaxel 
132 ng/µg and 7.3 ng/µg, 
respectively 
 [131] 
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EV-liposome mixing followed by 
freeze/thaw cycles 
Lipids (-PEG) / Alteration of the EV 
membrane composition 
[128] 
EV-micelle mixing followed by 
elevation of temperature (40°C) 
Lipids (-PEG) (-
nanobody®) 
/ Incorporation of targeting 
nanobodies® + PEGylation 
for an enhanced in vivo 
circulation time 
[127] 
EP electroporation; M+ metal electrodes; PBS phosphate buffered saline; GALA: a pH-sensitive fusogenic peptide; IP Intraperitoneal; 
PEG poly(ethylene glucol); N.R. not reported 
 
Table 3. Pre-formation loading of EVs 
Cargo  Producer cell Method of 
producer cell 
transfection 
Efficiency Target 
cell/Functional 
delivery?  
Remarks ref
Mir-143 and mir-
143BP1 
THP-1 Lipofection: 
LipoTrustTM EX 
Oligo + miRNA 
Estimation: 0.2-
0.25% of the 
stabilized miRNA 
present in the cell 
No functional 
delivery reported 
Differentiation of 
THP-1 cells into 
macrophages 
further stimulated 
miRNA secretion 
in EVs / immune-
EM confirmation of 
miRNA presence 
[255] 
mRNA HEK-293T Lipofection: 
Lipofectamine 
2000 + plasmid 
(+3’ UTR zipcode 
sequence)  
No absolute 
values reported 
per EV (~2 fold 
increase versus 
non-modified) 
No functional 
delivery reported 
 [39] 
mRNA (CD-UPRT) 
mRNA)/respective 
protein 
HEK-293T Lipofection: 
Lipofectamine 
2000 + plasmid 
(equipped with a 
strong promoter 
i.e. 
cytomegalovirus 
promotor) 
No absolute 
values 
HEI-193 cells Used as enzyme 
to functionalize a 
small molecule 
prodrug/sucrose 
gradient to confirm 
EV association 
[256] 
miRNA  HEK293 Lipofection: 
HiPerFect reagent  
+ plasmid (final 
concentration 50 
nM) 
No absolute 
values 
HCC70 cells GE11 peptide for 
EGFR targeting 
[132] 
miR-143, miR-146a, 
miR-155 
HEK293/COS-
7 
Lipofection: 
LipofectamineLTX 
+ plasmid 
overexpressing 
the respective pri-
miRNA  
2.57%, 15.6%, 
1.38% 
(percentage 
extracellular 
versus 
intracellular) 
COS-7 EV association 
confirmed using 
RNAse 
treatment/using 
the neutral 
sphingomyelinase 
inhibitor GW4869 
[153] 
mRNA: Cre 
recombinase 
mRNA(+protein?) 2 
MDA-MB-231 
mammary 
tumor cells 
Lipofection: 
lipofectamine 2000 
+ plasmid  
No absolute 
values 
MCF-7 and T47D 
mammary tumor 
cells 
Included delivery 
over long distance 
in vivo  
[155] 
(Cy3-tagged) miR-
223 
Macrophage 
(IL-4 
activated) 
Lipofection: X-
tremeGENE 
siRNA transfection 
reagent + miRNA 
No absolute 
values 
Breast cancer 
cells (SKBR3) 
 [257] 
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(FITC-tagged) miR-
150  
THP-1 cells Lipofection:  
lipofectamine 2000 
+ pre-miRNA  (400 
pmol per 60 mm 
dish) 
0.002 pmol 
miRNA per µg EV 
(protein 
concentration) 
HMEC-1 cells   [52] 
siRNA L929 cells Lipofection: 
lipofectamine 2000 
+ siRNA duplex 
(60 pmol per 105 
cells) 
0.001pmol siRNA 
per µg EV 
(protein 
concentration) 
S180 cells 0.4 pmol siRNA 
per mouse 
[258] 
Paclitaxel MSCs 
(SR4987 
cells) 
Incubation of 
producer cell with 
2000 ng/ml 
paclitaxel for 24h 
2.03 ng 
paclitaxel/mg 
protein 
CFPAC-1 (i.e. a 
paclitaxel 
sensitive 
adenocarcinoma 
cell line) 
 
EVs loaded with 
paclitaxel show an 
anti-proliferative 
effect 
[152] 
Adeno-associated 
virus (AAV) 
HEK 293T 
cells 
Calcium 
phosphate 
transfection of 
plasmids coding 
for different AAV 
components 
0.01% - 0.2% of 
the produced 
AAV are 
associated to EVs 
(depending on the 
AAV subtype) 
U87 and 293T 
cells 
 [160] 
TyA-GFP as model 
protein 
Jurkat T-cells Electroporation of 
the respective 
plasmid 
>10 fold increase 
compared to 
unanchored 
/. Targeting proteins 
to EVs via 
membrane 
anchors3 and the 
TyA-
oligomerization 
domain 
[156] 
siRNA (via plasmid) HEK 293T  Lipofectamine 
2000 + plasmid 
~0.15 pmol/µg EV Neuro2A RVG targeting (via 
fusion to the 
LAMP2 protein) 
[154] 
Iron oxide 
nanoparticles 
THP-1 Incubation in 
serum free 
medium 
 SKOV-3 cells  [259] 
1Bp: an aromatic benzene-pyridine analog was added to the 3′-overhang region of the RNA strand (higher nuclease resistance). 2 part 
of Cre-LoxP system to visualize functional protein/mRNA delivery to recipient cells. 3 e.g. myristoylation tag or PIP2-binding domain.  
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